![]() |
|||||
|
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() |
Gene: ZCCHC14 |
Gene summary for ZCCHC14 |
![]() |
Gene information | Species | Human | Gene symbol | ZCCHC14 | Gene ID | 23174 |
Gene name | zinc finger CCHC-type containing 14 | |
Gene Alias | BDG-29 | |
Cytomap | 16q24.2 | |
Gene Type | protein-coding | GO ID | GO:0003674 | UniProtAcc | Q8WYQ9 |
Top |
Malignant transformation analysis |
![]() |
![]() |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
23174 | ZCCHC14 | NAFLD1 | Human | Liver | NAFLD | 6.05e-04 | 5.23e-01 | -0.04 |
23174 | ZCCHC14 | HCC1_Meng | Human | Liver | HCC | 1.08e-21 | -9.04e-02 | 0.0246 |
23174 | ZCCHC14 | HCC2_Meng | Human | Liver | HCC | 7.04e-08 | -6.03e-02 | 0.0107 |
23174 | ZCCHC14 | HCC2 | Human | Liver | HCC | 1.37e-09 | 2.14e+00 | 0.5341 |
23174 | ZCCHC14 | S014 | Human | Liver | HCC | 2.39e-02 | 2.98e-01 | 0.2254 |
23174 | ZCCHC14 | S028 | Human | Liver | HCC | 1.05e-06 | 4.26e-01 | 0.2503 |
23174 | ZCCHC14 | S029 | Human | Liver | HCC | 3.68e-05 | 4.53e-01 | 0.2581 |
Page: 1 |
![]() |
Tissue | Expression Dynamics | Abbreviation |
Liver | ![]() | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
![]() |
![]() |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | ![]() |
Colorectum | SER | ![]() |
Colorectum | MSS | ![]() |
Colorectum | MSI-H | ![]() |
Colorectum | FAP | ![]() |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
![]() |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
Page: 1 |
![]() |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
Page: 1 |
Top |
Cell-cell communication analysis |
![]() |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
![]() |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
![]() |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
ZCCHC14 | SNV | Missense_Mutation | rs751003090 | c.1871N>A | p.Gly624Glu | p.G624E | Q8WYQ9 | protein_coding | tolerated(0.06) | benign(0.005) | TCGA-DF-A2KN-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | Unknown | I/II | Unknown | Unknown | SD |
ZCCHC14 | SNV | Missense_Mutation | novel | c.1847T>C | p.Val616Ala | p.V616A | Q8WYQ9 | protein_coding | tolerated(0.08) | benign(0.003) | TCGA-DI-A1BU-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Chemotherapy | paclitaxel | SD |
ZCCHC14 | SNV | Missense_Mutation | rs777372499 | c.670G>A | p.Val224Met | p.V224M | Q8WYQ9 | protein_coding | tolerated(0.73) | benign(0.009) | TCGA-EO-A22R-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
ZCCHC14 | SNV | Missense_Mutation | novel | c.1894N>A | p.Ala632Thr | p.A632T | Q8WYQ9 | protein_coding | deleterious(0) | benign(0.017) | TCGA-EO-A22U-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
ZCCHC14 | SNV | Missense_Mutation | novel | c.509N>A | p.Arg170Gln | p.R170Q | Q8WYQ9 | protein_coding | deleterious(0) | probably_damaging(0.978) | TCGA-EO-A3AV-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | carboplatin | CR |
ZCCHC14 | SNV | Missense_Mutation | novel | c.2757G>T | p.Gln919His | p.Q919H | Q8WYQ9 | protein_coding | deleterious(0.02) | benign(0.092) | TCGA-EY-A215-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
ZCCHC14 | deletion | Frame_Shift_Del | novel | c.2086delC | p.Leu696CysfsTer107 | p.L696Cfs*107 | Q8WYQ9 | protein_coding | TCGA-A5-A0GI-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | ||
ZCCHC14 | deletion | Frame_Shift_Del | novel | c.1027delN | p.Ala343GlnfsTer21 | p.A343Qfs*21 | Q8WYQ9 | protein_coding | TCGA-BS-A0UM-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Chemotherapy | adriamycin | SD | ||
ZCCHC14 | SNV | Missense_Mutation | novel | c.1949N>T | p.Ala650Val | p.A650V | Q8WYQ9 | protein_coding | deleterious_low_confidence(0.04) | benign(0.02) | TCGA-DD-AAEA-01 | Liver | liver hepatocellular carcinoma | Male | >=65 | I/II | Unknown | Unknown | SD |
ZCCHC14 | SNV | Missense_Mutation | novel | c.2284N>G | p.Asn762Asp | p.N762D | Q8WYQ9 | protein_coding | tolerated_low_confidence(0.13) | benign(0.01) | TCGA-G3-A7M5-01 | Liver | liver hepatocellular carcinoma | Male | >=65 | I/II | Unknown | Unknown | SD |
Page: 1 2 3 4 5 6 7 8 9 10 |
Top |
Related drugs of malignant transformation related genes |
![]() |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |